ClinicalTrials.gg
CompletedNCT03262376Updated Jan 7, 2019

Minerals and Botanicals for Acute Stress

An interventional study of Minerals + Vitamins and Botanical A in Stress and Anxiety, sponsored by University of Leeds. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-07.

Primary conditionAnxiety Disorders(the registry's first term)UnverifiedIs this wrong?The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by University of Leeds · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The objective of this acute intervention study is to examine the potential of minerals combined with botanicals to demonstrate unique and synergistic effects on oscillatory brain activity, cognitive performance, and stress reduction (endocrine, sympathetic, and subjective parameters) under conditions of acute stress in moderately stressed individuals

Read the detailed description

Botanicals in isolation or combined, will be administered with a mineral and vitamin complex to moderately stressed, healthy adults in a parallel groups fashion in this randomised placebo controlled trial. Oscillatory brain activity (EEG) during rest and performance on cognitive tasks of attention will be examined after treatment intake under conditions of acute laboratory stress. The effects of treatments on stress responses (cardiovascular, subjective and cortisol responses) will also be assessed.

02

Conditions studied

  • Stress
  • Anxiety

Browse trials for

Keywords

  • Stress
  • Anxiety
  • Cortisol
  • Vitamins
  • Botanicals
  • Minerals
03

In context

Anxiety Disorders Unverified

7,207 studies on the registry are indexed under Anxiety Disorders; 1,682 are open to participants now.

This study's enrollment of 100 is above the median of 80 across 6,057 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

University of Leeds is the lead sponsor of 206 studies on the registry; 25 are open to participants now.

Compared within Anxiety Disorders, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults capable of giving
  • Male and Female
  • ≥18 - ≤50 years of age (premenopausal if female)
  • Effective taken in females
  • Women in luteal menstrual phase
  • (BMI) ≥18 and ≤30 kg/m2
  • Normal vision or corrected to normal
  • Moderately stressed (subjective report)

Exclusion criteria

Exclusion Criteria:

  • No known intolerance to minerals, vitamins or botanicals
  • Intake of prescribed medication except
  • Intake of any regular medication/supplements
  • History of significant hypertensive, hepatic, renal, pulmonary, gastro-intestinal, endocrinological, neurologic, haematological, psychiatric (inc. mood disorders), cardiac or allergic disease which is to the study
  • Hypertension (self-report or resting blood pressure >160/95 mmHg)
  • Diabetes (T1 or T2)
  • Smoking more than occasional cigarettes (>5/day)
  • Pregnant or lactating
  • Previous participation in a stress study involving the Trier Social Stress Test
  • Night-working/shift work
  • Recreational drug use
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Mineral + vits + botanical A

    Mineral and vitamin complex combined with Botanical A

    Dietary Supplement: Minerals + Vitamins · Dietary Supplement: Botanical A

  • Experimental
    Mineral + vits + botanical B

    Mineral and vitamin complex combined with Botanical B

    Dietary Supplement: Minerals + Vitamins · Dietary Supplement: Botanical B

  • Experimental
    Mineral+vits +botanical A+Botanical B

    Mineral and vitamin complex combined with Botanical A and Botanical B

    Dietary Supplement: Minerals + Vitamins · Dietary Supplement: Botanical A · Dietary Supplement: Botanical B

  • Placebo comparator
    Placebo

    Cellulose crystalline placebo

    Other: Placebo

Interventions

  • Dietary supplementMinerals + Vitamins

    Drug pages: Minerals · Vitamins

    A mineral and vitamin tablet

  • Dietary supplementBotanical A

    Botanical extract administered in capsule form

  • Dietary supplementBotanical B

    Botanical extract administered in capsule form

  • OtherPlacebo

    Cellulose crystalline tablet

06

What researchers measure

Primary outcomes

  1. Oscillatory brain activity during the rested state and attentional processing (EEG; Biosemi Active2, 64-channel, DC amplifier, 24-bit resolution system)

    The effect of treatment on oscillatory brain activity during the rested state and during attentional task processing after stress exposure

    Time frame: 30 minute period, approximately 65 minutes post treatment intake

Secondary outcomes

  1. Subjective stress (Stress & Arousal Checklist; Mackay et al., 1978)

    The effect of treatment on subjective stress responses to stress induction

    Time frame: Acute responses to stress induction from pre-treatment intake to approximately 8 hours post-treatment intake

  2. Subjective mood (Profile of Mood States [MCNair et al., 1971] & Bond Visual analogue scales, 1974)

    The effect of treatment on subjective mood responses to stress induction

    Time frame: Acute responses to stress induction from pre-treatment intake to approximately 8 hours post-treatment intake

  3. Subjective anxiety (Spielberger State Trait Anxiety Inventory, 1983)

    The effect of treatment on subjective anxiety responses to stress induction

    Time frame: Acute responses to stress induction from pre-treatment intake to approximately 8 hours post-treatment intake

  4. Cognitive performance (Digit attention switching & threat vs neutral dot probe task)

    The effect of treatment on reaction time and accuracy performance on two cognitive tasks of attention

    Time frame: 20 minute period (comprising two distinct tasks) approximately 75 minutes post treatment intake

  5. Blood pressure

    The effect of treatment on blood pressure responses to stress induction

    Time frame: Acute responses to stress induction from pre-treatment intake to approximately 8 hours post-treatment intake

  6. Heart rate

    The effect of treatment on heart rate variability before and after stress induction

    Time frame: Acute responses to stress induction from pre-treatment intake to approximately 8 hours post-treatment intake

  7. Salivary cortisol

    The effect of treatment on salivary cortisol responses to stress induction

    Time frame: Acute responses to stress induction from pre-treatment intake to approximately 8 hours post-treatment intake

  8. Event related potentials (EEG; Biosemi Active2, 64-channel, DC amplifier, 24-bit resolution system)

    The effect of treatment on event related potentials during execution of attentional processing

    Time frame: 20 minute period (comprising two distinct tasks) approximately 75 minutes post treatment intake

07

Study locations

1 site
  • Human Appetite Research Unit, University of Leeds
    Leeds, West Yorkshire LS29JT, United Kingdom
08

References and documents

Publications

  • Boyle NB, Dye L, Lawton CL, Billington J. A Combination of Green Tea, Rhodiola, Magnesium, and B Vitamins Increases Electroencephalogram Theta Activity During Attentional Task Performance Under Conditions of Induced Social Stress. Front Nutr. 2022 Jul 22;9:935001. doi: 10.3389/fnut.2022.935001. eCollection 2022. PubMed 35938130 ↗
  • Boyle NB, Billington J, Lawton C, Quadt F, Dye L. A combination of green tea, rhodiola, magnesium and B vitamins modulates brain activity and protects against the effects of induced social stress in healthy volunteers. Nutr Neurosci. 2022 Sep;25(9):1845-1859. doi: 10.1080/1028415X.2021.1909204. Epub 2021 Apr 26. PubMed 33896388 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Dec 2018, 12 months.

Of 3,836 non-industry interventional studies with no phase under Anxiety Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's 12 months is close to that.

Counting every sponsor, half of 3,938 studies reached it within 12 months; a quarter within 5 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2017
First posted
Aug 25, 2017
StartActual
Dec 4, 2017
Primary completionActual
Dec 12, 2018
CompletionActual
Dec 12, 2018
Last update
Jan 7, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03262376
Responsible party
Prof Louise Dye (Professor of Nutrition and Behaviour, University of Leeds) — Principal investigator
First posted
Aug 25, 2017
Start date
Dec 4, 2017
Primary completion
Dec 12, 2018
Completion
Dec 12, 2018
Last update
Jan 7, 2019

Study contacts

Louise Dye, PhD
principal investigator · University of Leeds

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Minerals · Vitamins

Start the discussion